Ipreziv

RSS

azilsartan medoxomil

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Ipreziv has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 19/12/2014

Authorisation details

Product details
Name
Ipreziv
Agency product number
EMEA/H/C/002517
Active substance
Azilsartan medoxomil
International non-proprietary name (INN) or common name
azilsartan medoxomil
Therapeutic area (MeSH)
Hypertension
Anatomical therapeutic chemical (ATC) code
C09CA09
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Takeda Pharma A/S
Revision
4
Date of issue of marketing authorisation valid throughout the European Union
07/12/2011
Contact address
Dybendal Alle 10
2630 Taastruup
United Kingdom

Product information

27/10/2014 Ipreziv - EMEA/H/C/002517 - A31/0006

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

Therapeutic indication

Ipreziv is indicated for the treatment of essential hypertension in adults.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
Average
2 ratings